Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589497931> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2589497931 endingPage "e14555" @default.
- W2589497931 startingPage "e14555" @default.
- W2589497931 abstract "e14555 Background: Increasing evidence indicates a role of the local rennin-angitensin system (RAS) in tumor growth, suggesting potential of RAS as a target for cancer treatment. Our retrospective analysis showed inhibition of RAS was associated with better progression-free survival and overall survival in patients with advanced pancreatic cancer receiving gemcitabine (Br J Cancer. 2010;103:1644-8). This study was conducted to investigate the maximum-tolerated dose (MTD) of candesartan, an angiotensin receptor blocker, in combination with gemcitabine in patients with advanced pancreatic cancer (UMIN-CTR 000002152). Methods: Candesartan was administered orally at escalating dose (4 mg, 8 mg, 16 mg and 32 mg) qd daily and gemcitabine was administered 1,000 mg/m2 30min i.v. day 1, 8, 15, repeated every 4 weeks. There were no dose escalations within each patient. Eligible criteria were unresectable locally advanced or metastatic pancreatic cancer without any prior treatment, ECOG PS 0-2, normal renal function and without hypertension or hypotension. DLT was defined as grade 4 hematological toxicities, Grade 2 hypotension, abnormal creatinine or potassium and grade 3 or 4 other non-hematological toxicities. MTD was defined when 2 or more patients in a cohort of 3 patients or when 3 or more patients in a cohort of 6 patients experienced DLT. Results: Between July 2009 and Oct 2010, 14 patients (4 mg: 3 patients, 8 mg: 3 patients, 16 mg: 6 patients, 32 mg: 2 patients) were enrolled in this trial. The median age, 60, male:female, 5:9, PS 0:1, 8:6, locally advanced, 43%. One of 6 patients at 16 mg demonstrated DLT of grade 4 neutropenia and 2 of 2 patients at 32mg demonstrated DLT of grade 2 hypotension. Tumor response by RECIST was SD in 11, PD in 1, and NE in 2. Response rate was 0% but disease control rate (DCR) was 79%. Median progression-free survival (PFS) was 8.1 months and 1-year survival was 65% after a median observational period of 9.8 months. Conclusions: The recommended dose of candesartan in combination with gemcitabine was 16 mg. The results of DCR and PFS appeared promising." @default.
- W2589497931 created "2017-03-03" @default.
- W2589497931 creator A5000200388 @default.
- W2589497931 creator A5010319344 @default.
- W2589497931 creator A5019243930 @default.
- W2589497931 creator A5026907725 @default.
- W2589497931 creator A5032191719 @default.
- W2589497931 creator A5041726256 @default.
- W2589497931 creator A5048055102 @default.
- W2589497931 creator A5048629855 @default.
- W2589497931 creator A5049263315 @default.
- W2589497931 creator A5060049548 @default.
- W2589497931 creator A5062029828 @default.
- W2589497931 creator A5073049896 @default.
- W2589497931 date "2011-05-20" @default.
- W2589497931 modified "2023-09-26" @default.
- W2589497931 title "Phase I study of a combination therapy of gemcitabine and candesartan in patients with advanced pancreatic cancer: GECA-1 study." @default.
- W2589497931 doi "https://doi.org/10.1200/jco.2011.29.15_suppl.e14555" @default.
- W2589497931 hasPublicationYear "2011" @default.
- W2589497931 type Work @default.
- W2589497931 sameAs 2589497931 @default.
- W2589497931 citedByCount "0" @default.
- W2589497931 crossrefType "journal-article" @default.
- W2589497931 hasAuthorship W2589497931A5000200388 @default.
- W2589497931 hasAuthorship W2589497931A5010319344 @default.
- W2589497931 hasAuthorship W2589497931A5019243930 @default.
- W2589497931 hasAuthorship W2589497931A5026907725 @default.
- W2589497931 hasAuthorship W2589497931A5032191719 @default.
- W2589497931 hasAuthorship W2589497931A5041726256 @default.
- W2589497931 hasAuthorship W2589497931A5048055102 @default.
- W2589497931 hasAuthorship W2589497931A5048629855 @default.
- W2589497931 hasAuthorship W2589497931A5049263315 @default.
- W2589497931 hasAuthorship W2589497931A5060049548 @default.
- W2589497931 hasAuthorship W2589497931A5062029828 @default.
- W2589497931 hasAuthorship W2589497931A5073049896 @default.
- W2589497931 hasConcept C121608353 @default.
- W2589497931 hasConcept C126322002 @default.
- W2589497931 hasConcept C126894567 @default.
- W2589497931 hasConcept C143998085 @default.
- W2589497931 hasConcept C170493617 @default.
- W2589497931 hasConcept C2780036600 @default.
- W2589497931 hasConcept C2780210213 @default.
- W2589497931 hasConcept C2780258809 @default.
- W2589497931 hasConcept C2780306776 @default.
- W2589497931 hasConcept C2908929049 @default.
- W2589497931 hasConcept C71924100 @default.
- W2589497931 hasConcept C72563966 @default.
- W2589497931 hasConcept C90924648 @default.
- W2589497931 hasConceptScore W2589497931C121608353 @default.
- W2589497931 hasConceptScore W2589497931C126322002 @default.
- W2589497931 hasConceptScore W2589497931C126894567 @default.
- W2589497931 hasConceptScore W2589497931C143998085 @default.
- W2589497931 hasConceptScore W2589497931C170493617 @default.
- W2589497931 hasConceptScore W2589497931C2780036600 @default.
- W2589497931 hasConceptScore W2589497931C2780210213 @default.
- W2589497931 hasConceptScore W2589497931C2780258809 @default.
- W2589497931 hasConceptScore W2589497931C2780306776 @default.
- W2589497931 hasConceptScore W2589497931C2908929049 @default.
- W2589497931 hasConceptScore W2589497931C71924100 @default.
- W2589497931 hasConceptScore W2589497931C72563966 @default.
- W2589497931 hasConceptScore W2589497931C90924648 @default.
- W2589497931 hasIssue "15_suppl" @default.
- W2589497931 hasLocation W25894979311 @default.
- W2589497931 hasOpenAccess W2589497931 @default.
- W2589497931 hasPrimaryLocation W25894979311 @default.
- W2589497931 hasRelatedWork W1969578744 @default.
- W2589497931 hasRelatedWork W2005537476 @default.
- W2589497931 hasRelatedWork W2059464886 @default.
- W2589497931 hasRelatedWork W2071805383 @default.
- W2589497931 hasRelatedWork W2165480504 @default.
- W2589497931 hasRelatedWork W2171607164 @default.
- W2589497931 hasRelatedWork W2319496893 @default.
- W2589497931 hasRelatedWork W2376347278 @default.
- W2589497931 hasRelatedWork W2752933315 @default.
- W2589497931 hasRelatedWork W4280548038 @default.
- W2589497931 hasVolume "29" @default.
- W2589497931 isParatext "false" @default.
- W2589497931 isRetracted "false" @default.
- W2589497931 magId "2589497931" @default.
- W2589497931 workType "article" @default.